Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF CULMERCICLIB IN COMBINATION WITH FULVESTRANT FOR FIRST-LINE TREATMENT OF HR-POSITIVE AND HER2-NEGATIVE ADVANCED BREAST CANCER2025.03.24
-
FINAL DIVIDEND FOR 20242025.03.20
-
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 20242025.03.20
-
VOLUNTARY ANNOUNCEMENT - RESULTS FROM PHASE IB/IIA CLINICAL STUDY OF FIRST-IN-CLASS JAK/ROCK INHIBITOR "ROVADICITINIB" PUBLISHED IN BLOOD2025.03.10
-
VOLUNTARY ANNOUNCEMENT - ENTERING INTO AN EXCLUSIVE COOPERATION AGREEMENT WITH DELOVA BIOTECH FOR QP0012025.03.06
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 20252025.03.03
-
CHANGE OF HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE2025.03.03
-
NOTIFICATION OF BOARD MEETING2025.03.03